AIRNECFLU
Dead / Abandoned — Abandoned — no statement of use filed (as of 01 Apr 2024)
What this means for you
This application is over — abandoned 01 Apr 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97125105
- Mark type
- Stylized text
- Filed
- 15 Nov 2021
- Published for opposition
- 04 Jul 2023
- Abandoned
- 01 Apr 2024
- Attorney of record
- Joe McKinney Muncy
Goods and services
- Class 005 — Pharmaceuticals: Antiviral drugs; antibiotics; antibiotics for animals; chemical reagent for medical purposes; chemical reagent for veterinary purposes; germicides for animals; germicides; biocides for medical purposes; germicide for human use; biocides for veterinary purposes; medicines for human purposes namely, for treatment of virus infection, neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, hyperactivity, anxiety, bipolar disorder, and other central nervous system disorders; medicines for human purposes namely, for improving basic behavioral functioning, suicidal ideation and behavior, sensorimotor gating, pain threshold, memory and cognitive functioning and loss weight; sedatives; nervines for pharmaceutical or medical purposes, namely, for treating attention deficit hyperactivity disorder (ADHD), schizophrenia, pain, depression, bipolar disorder, eating disorder, addiction disorder, personality disorder, psychotic disorder, tic disorder, post-traumatic stress disorder, anxiety, social anxiety disorder, panic disorder, autism, Asperger's disorder, obsessive-compulsive disorder (OCD), learning disorder, Tourette's syndrome, mild cognitive disorder (MCI), benign forgetfulness, closed head injury, dementia, vascular dementia, Alzheimer's disorder, frontotemporal dementia, Parkinson's disorder, Huntington's disease, nocturnal enuresis, blepharospasm, non-epileptic seizure, premenstrual syndrome, and amyotrophic lateral sclerosis (ALS); gases for pharmaceutical or medical purposes, namely, for treating attention deficit hyperactivity disorder (ADHD), schizophrenia, pain, depression, bipolar disorder, eating disorder, addiction disorder, personality disorder, psychotic disorder, tic disorder, post-traumatic stress disorder, anxiety, social anxiety disorder, panic disorder, autism, Asperger's disorder, obsessive-compulsive disorder (OCD), learning disorder, Tourette's syndrome, mild cognitive disorder (MCI), benign forgetfulness, closed head injury, dementia, vascular dementia, Alzheimer's disorder, frontotemporal dementia, Parkinson's disorder, Huntington's disease, nocturnal enuresis, blepharospasm, non-epileptic seizure, premenstrual syndrome, and amyotrophic lateral sclerosis (ALS);nasal spray for treating respiratory tract infections caused by viruses or bacteria; oral spray for treating respiratory tract infections caused by viruses or bacteria
Owner
- SyneuRx International (Taiwan) Corp., New Taipei City, TW
- SyneuRx International (Taiwan) Corp., New Taipei City, TW
Prosecution history
- 01 Apr 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 01 Apr 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 29 Aug 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Jul 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Jul 2023 — PUBLISHED FOR OPPOSITION
- 14 Jun 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Jun 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 02 May 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 02 May 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 02 May 2023 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 11 Feb 2023 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 11 Feb 2023 — FINAL REFUSAL E-MAILED
- 11 Feb 2023 — FINAL REFUSAL WRITTEN
- 29 Dec 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 29 Dec 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE